Adimmune Corp (TW:4142) — Market Cap & Net Worth
Market Cap & Net Worth: Adimmune Corp (4142)
Adimmune Corp (TW:4142) has a market capitalization of $229.08 Million (NT$7.27 Billion) as of September 17, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #16106 globally and #737 in its home market, demonstrating a -1.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adimmune Corp's stock price NT$17.25 by its total outstanding shares 421508000 (421.51 Million). Also see Adimmune Corp assets under control for a full breakdown of the balance sheet.
Adimmune Corp Market Cap History: 2015 to 2026
Adimmune Corp's market capitalization history from 2015 to 2026. Data shows change from $328.31 Million to $229.08 Million (-2.63% CAGR). Also see 4142 cash generation efficiency for how efficiently the company converts equity into cash flow.
Adimmune Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adimmune Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Adimmune Corp (4142) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.17x
Adimmune Corp's market cap is 0.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $328.31 Million | $290.74 Million | -$761.09 Million | 1.13x | N/A |
| 2016 | $300.67 Million | $606.73 Million | -$595.35 Million | 0.50x | N/A |
| 2017 | $265.80 Million | $562.74 Million | -$760.18 Million | 0.47x | N/A |
| 2018 | $267.12 Million | $822.37 Million | -$617.84 Million | 0.32x | N/A |
| 2019 | $332.91 Million | $1.30 Billion | -$280.68 Million | 0.26x | N/A |
| 2020 | $738.20 Million | $1.87 Billion | $1.24 Billion | 0.39x | 0.59x |
| 2021 | $592.94 Million | $1.64 Billion | $43.07 Million | 0.36x | 13.77x |
| 2022 | $472.76 Million | $2.25 Billion | $290.98 Million | 0.21x | 1.62x |
| 2023 | $440.23 Million | $1.79 Billion | -$639.89 Million | 0.25x | N/A |
| 2024 | $266.92 Million | $1.56 Billion | -$242.75 Million | 0.17x | N/A |
Competitor Companies of 4142 by Market Capitalization
Companies near Adimmune Corp in the global market cap rankings as of September 17, 2026. Review how tangible is Adimmune Corp's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Adimmune Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Adimmune Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Adimmune Corp's market cap moved from $328.31 Million to $ 229.08 Million, with a yearly change of -2.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$229.08 Million | -8.97% |
| 2025 | NT$251.65 Million | -5.72% |
| 2024 | NT$266.92 Million | -39.37% |
| 2023 | NT$440.23 Million | -6.88% |
| 2022 | NT$472.76 Million | -20.27% |
| 2021 | NT$592.94 Million | -19.68% |
| 2020 | NT$738.20 Million | +121.74% |
| 2019 | NT$332.91 Million | +24.63% |
| 2018 | NT$267.12 Million | +0.50% |
| 2017 | NT$265.80 Million | -11.60% |
| 2016 | NT$300.67 Million | -8.42% |
| 2015 | NT$328.31 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Adimmune Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $229.08 Million USD |
| MoneyControl | $229.08 Million USD |
| MarketWatch | $229.08 Million USD |
| marketcap.company | $229.08 Million USD |
| Reuters | $229.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adimmune Corp
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops Adim… Read more